The Akt inhibitor perifosine was one of the earliest compounds evaluated in DIPG models40 and translated to the clinic41; sensitivity to the mTOR inhibitor TAK228 (MLN0128)42 and dual PI3K-mTOR inhibitor BKM12036 have also recently been reported and an ongoing stratified medicine trial in DIPG patients includes everolimus as one of three investigational arms (NCT02233049). This evidence concerns the gene PIK3CA and diffuse intrinsic pontine glioma.